top of page
Resource Hub
For more on the resources IPAC provides and links to external information please read more below.
In 4Q 2021, the International Pharmaceutical Aerosol Consortium (IPAC) conducted a survey of its member companies regarding the manufacture of HFC MDIs in the European Union, including volumes imported and exported. This document summarises the compiled, aggregate survey responses from IPAC members. All data refers to calendar year 2020.
On 5 May 2021, IPAC presented this work at the Respiratory Drug Delivery conference. The paper provides context on the evolving global legislative and regulatory landscape relevant to medical propellants and shares IPAC’s views on the most effective holistic, patient-care approach to the global environmental challenges of inhaled therapies.
IPAC-RS was formed as part of the International Pharmaceutical Aerosol Consortium (IPAC) in 1999 and established in 2001 as a separate Consortium, with the mission to enhance the quality and availability to patients of orally inhaled and nasal drug products (OINDP) through scientifically driven advancements related to development and regulation of these products.
bottom of page